Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma

Bitget2026/09/25 14:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bristol Myers Squibb won FDA accelerated approval for ZENBEXUS (iberdomide) with daratumumab and dexamethasone in multiple myeloma.
Cleared for adults with at least one prior line including a proteasome inhibitor and an immunomodulatory agent.
Decision based on MRD-negative complete response; continued approval hinges on confirmatory progression-free survival results in an ongoing cohort.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260924614211) on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS combo in multiple myeloma

You may also like

Crypto prices